GSK confirms plan to buy cancer firm IDRx for $1bn | pharmaphorum

2 days ago · GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.

$1
OFF

GSK Confirms Plan To Buy Cancer Firm IDRx For $1bn | Pharmaphorum

2 weeks from now

2 days ago · GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.

pharmaphorum.com

$1
OFF

Is GSK Prepping A $1bn Takeover Bid For IDRx? - Pharmaphorum

2 weeks from now

6 days ago · GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour.

pharmaphorum.com

$1
OFF

GSK Nears $1bn Deal For Biotech Developing Drug For Rare Tumour

2 weeks from now

Jan 8, 2025 · GSK is nearing a $1bn deal to buy a US biotech developing a treatment for rare gastrointestinal tumours, as the UK drugmaker races to expand its oncology business.

ft.com

$1
OFF

GSK Nears $1 Billion Deal For Biotech Company IDRx

2 weeks from now

6 days ago · GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its growing oncology …

bloomberg.com

$1
OFF

GSK Is Said To Be Nearing $1B Deal To Acquire U.S. Biotech IDRx

2 weeks from now

British pharma giant GSK (NYSE:GSK) is closing in on a $1B buyout deal to acquire IDRx, a U.S. biotech focused on developing drugs for rare gastrointestinal tumors, The Financial Times …

msn.com

$1
OFF

IDRx | Pharmaphorum

2 weeks from now

6 days ago · Is GSK prepping a $1bn takeover bid for IDRx? GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal …

pharmaphorum.com

$1
OFF

GSK In Talks To Buy U.S. Rare Tumor Specialist IDRx For Up To $1 ...

2 weeks from now

6 days ago · --Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 …

morningstar.com

$1
OFF

GSK Nears $1B Deal To Acquire IDRx - Grafa.com

2 weeks from now

Jan 8, 2025 · British pharmaceutical giant GSK (NYSE:GSK) is reportedly in advanced talks to acquire IDRx, a privately-held biotechnology company focused on developing treatments for a …

grafa.com

$1
OFF

GSK Nearing Deal To Acquire US Biotech IDRx For Up To $1 Billion

2 weeks from now

Jan 8, 2025 · -- GSK is in advanced discussions to acquire privately-owned US biotech company IDRx for up to $1 billion, the Financial Times reported Wednesday, citing people close to the …

marketscreener.com

$1
OFF

GSK Swooping To Buy US Biotech IDRx For $1bn - Report

2 weeks from now

Jan 8, 2025 · UK pharma giant GSK PLC is close to buying US biotech startup IDRx for $1 billion to boost its cancer drug business, the Financial Times has reported.

proactiveinvestors.co.uk

$1
OFF

GSK In Talks To Buy US Biotech Company For $1bn

2 weeks from now

6 days ago · The FTSE 100 company plans the bolt-on purchase of IDRx, a cancer drug specialist based in Cambridge, Massachusetts

thetimes.com

$1
OFF

GSK Swooping To Buy US Biotech IDRx For $1bn - Report

2 weeks from now

Jan 8, 2025 · UK pharma giant GSK PLC is close to buying US biotech startup IDRx for $1 billion to boost its cancer drug business, the Financial Times has reported. Backed by a raft of …

proactiveinvestors.com

$1
OFF

GSK Nearing $1 Billion Deal To Acquire US Biotech IDRx, FT Reports

2 weeks from now

Jan 8, 2025 · GSK Nearing $1 Billion Deal to Acquire US Biotech IDRx, FT Reports

marketscreener.com

$1
OFF

GSK Nears $1B Deal To Buy U.S. Biotech IDRx (GSK:NYSE)

2 weeks from now

Jan 8, 2025 · GSK (GSK) stock is in focus as the company is nearing a $1B deal to acquire IDRx, a private biotech focused on a rare gastrointestinal tumor. Read more here.

seekingalpha.com

$1
OFF

GlaxoSmithKline Plc Sponsored ADR (GSK.US) Plans To Spend $1 …

2 weeks from now

According to informed sources, GlaxoSmithKline plc Sponsored ADR (GSK.US) is in negotiations to acquire the biotechnology company IDRx, with the valuation of the latter potentially reaching …

gmteight.com

$1
OFF

GSK Builds Neuro, Cancer Pipeline With Trio Of Deals - Pharmaphorum

2 weeks from now

3 days ago · GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour.

pharmaphorum.com

$1
OFF

GSK Close To US$1b Deal For Biotech Company IDRx, Bloomberg …

2 weeks from now

6 days ago · GSK plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its growing oncology …

theedgemalaysia.com

$1
OFF

GSK In Talks To Buy U.S. Rare Tumor Specialist IDRx For Up To $1 ...

2 weeks from now

6 days ago · --Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 …

marketscreener.com

$1
OFF

A Few Of 2022’s Biggest Pharma Trends - Pharmaphorum

2 weeks from now

6 days ago · GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour.

pharmaphorum.com

$1
OFF

Daiichi Sankyo’s Ezharmia Cleared In Japan For Rare Lymphoma

2 weeks from now

Jun 24, 2024 · GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour.

pharmaphorum.com

FAQs about GSK confirms plan to buy cancer firm IDRx for $1bn | pharmaphorum Coupon?

Is GSK (GSK) on a $1B deal with idrx?

GSK (GSK) stock is in focus as the company is nearing a $1B deal to acquire IDRx, a private biotech focused on a rare gastrointestinal tumor. Read more here. ...

Could GSK & idrx opt out of a biotech deal?

As discussions continue, the people added that GSK (NYSE: GSK) and IDRx could opt out of the deal, or the company will attract a new buyer. A clinical-stage biotech founded in 2022, IDRx has private equity firm Blackstone (BL) and venture capital firms Andreessen Horowitz and RA Capital among its notable investors. ...

Will GSK & idrx opt out of the JPMorgan healthcare deal?

They noted that the deal is expected to be announced before next week's JPMorgan Healthcare conference. As discussions continue, the people added that GSK (NYSE: GSK) and IDRx could opt out of the deal, or the company will attract a new buyer. ...

How did GSK perform in the first three quarters of 2024?

Sales of cancer drugs at GSK increased 94 per cent year on year to more than $1bn in the first three quarters of 2024. This included a contribution from the drug Ojjaara, which the company acquired as part of its $1.7bn purchase of Sierra Oncology in 2022. ...

Will idrx go public?

IDRx had also been working on plans to go public. GSK declined to comment. IDRx did not immediately respond to request for comment. IDRx is conducting early-stage trials of its targeted therapy for patients with a type of cancer called gastrointestinal stromal tumour, or Gist, which affects between 4,000 and 6,000 people each year in the US. ...

Who is buying idrx?

The UK group is in advanced talks to buy privately owned biotech IDRx, which has venture capital firms Andreessen Horowitz and RA Capital as well as private equity giant Blackstone among its backers, according to people close to the discussions. ...